These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32224045)

  • 21. Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial.
    Portier A; Gossec L; Tubach F; Alfaiate T; Pham T; Saraux A; Soubrier M; Schaeverbeke T; Maillefert JF; Mariette X; Hajage D; Fautrel B
    Joint Bone Spine; 2017 Oct; 84(5):577-581. PubMed ID: 27932278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months.
    Bae SC; Cho SK; Won S; Lee HS; Lee SH; Kang YM; Lee SH; Lee YA; Choe JY; Chung WT; Suh CH; Shim SC; Lee J; Yoon BY; Kim DW; Lee SS; Yoo WH; Kim JS; Jung YO; Nah SS; Lee CK; Song GG; Choi SJ; Joung CI; Koh H; Kim YJ
    Int J Rheum Dis; 2018 May; 21(5):1001-1009. PubMed ID: 29878615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responsiveness and sensitivity of PROMs to change in disease activity status in early and established rheumatoid arthritis.
    Looijen AEM; van Mulligen E; Vonkeman HE; van der Helm-van Mil AHM; de Jong PHP
    Rheumatology (Oxford); 2024 Apr; ():. PubMed ID: 38574380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
    Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
    Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
    Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
    Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings).
    Chaudhary H; Bittar M; Daoud A; Magrey M
    Curr Rheumatol Rep; 2024 May; 26(5):155-163. PubMed ID: 38332457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of quality of life, functional status, depression and fatigue in early arthritis: comparison between clinically suspect arthralgia, unclassified arthritis and rheumatoid arthritis.
    Torlinska B; Raza K; Filer A; Jutley G; Sahbudin I; Singh R; de Pablo P; Rankin E; Rhodes B; Amft N; Justice E; McGrath C; Baskar S; Trickey J; Calvert M; Falahee M
    BMC Musculoskelet Disord; 2024 Apr; 25(1):307. PubMed ID: 38643104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of different (rheumatoid) arthritis phenotypes on patients' lives.
    Luurssen-Masurel N; Weel AEAM; Hazes JMW; de Jong PHP;
    Rheumatology (Oxford); 2021 Aug; 60(8):3716-3726. PubMed ID: 33237330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.
    Aletaha D; Maa JF; Chen S; Park SH; Nicholls D; Florentinus S; Furtner D; Smolen JS
    Ann Rheum Dis; 2019 Dec; 78(12):1609-1615. PubMed ID: 31434637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.
    Ghiti Moghadam M; Ten Klooster PM; Vonkeman HE; Kneepkens EL; Klaasen R; Stolk JN; Tchetverikov I; Vreugdenhil SA; van Woerkom JM; Goekoop-Ruiterman YPM; Landewé RBM; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):516-524. PubMed ID: 28692770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hospital Anxiety and Depression Scale Score Is an Independent Factor Associated With the EuroQoL 5-Dimensional Descriptive System in Patients With Rheumatoid Arthritis.
    Hattori Y; Katayama M; Kida D; Kaneko A
    J Clin Rheumatol; 2018 Sep; 24(6):308-312. PubMed ID: 29742541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
    van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
    BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.
    Lie E; Woodworth TG; Christensen R; Kvien TK; Bykerk V; Furst DE; Bingham CO; Choy EH;
    Ann Rheum Dis; 2014 Oct; 73(10):1781-7. PubMed ID: 23852690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.